Supernus Pharmaceuticals | SUPN - Operating Expenses

Stock Price
48.38
Daily Change
-0.40 -0.82%
Monthly
-2.06%
Yearly
20.95%
Q1 Forecast
46.68

Supernus Pharmaceuticals reported $252.29M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
ANI Pharmaceuticals USD 505.82M 309.62M Sep/2025
Aurora Cannabis CAD 146.03M 27.79M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Corcept Therapeutics USD 197.42M 29.66M Sep/2025
Eisai JPY 183.69B 1.78B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Novo Nordisk DKK 42.77B 3.48B Jun/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Xeris Pharmaceuticals USD 67.65M 590K Sep/2025